The healthcare technology company has secured two new contracts worth a combined £1.3 million to provide neuroimaging services for clinical trials in Alzheimer's Disease and Friedreich's Ataxia.
The healthcare technology company has secured a strategic partnership with a leading Alzheimer's research organization, gaining access to valuable study data to advance its biomarker analytics capabilities.
The healthcare technology company reports revenues are anticipated to exceed expectations for the year, driven by positive sales momentum and strategic execution.
The medical imaging analytics company IXICO has granted share options to its Chief Technology Officer, Chief Business Officer and VP Global Business Development.
The healthcare technology company has assisted in the FDA clearance of a new blood-based test that will help advance diagnosis and drug development in Alzheimer's disease.
The healthcare data analytics company has announced a change in shareholding, with no further details provided.
The neuroscience imaging and biomarker analytics firm reported a 26% increase in revenue and improved gross margins, while still operating at a loss. New contracts and diversification efforts show promise.
The healthcare company announces a change in the investment manager and name of one of its shareholders, with no impact on its own operations.
The healthcare technology company will release its interim results and host an investor presentation next month.
The medical imaging analytics company reports robust first-half performance, with revenues up 26% and improved profitability, positioning it well for the remainder of the year.